Trial Profile
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-1
- Sponsors AstraZeneca
- 22 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2022.
- 07 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 03 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.